Studies have shown that anti-DR5 antibodies induce apoptosis in activated HSCs, exhibiting anti-fibrotic effects and presenting a potential therapeutic approach for liver fibrosis (You et al., 2021). Here, TNFRSF10B is linked to Hepatic fibrosis.